Riboscience

Focus: Riboscience is a clinical-stage biotechnology company focused on ribose-based therapies for oncology and infectious diseases. The company is headquartered in Sunnyvale, CA and operates as a pre-revenue biotech with a focused pipeline.

Oncology Infectious diseases and cancer

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Open Jobs

About Riboscience

AI assessmentNot Hiring

No open roles listed right now. Follow Riboscience to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RBS2418

Expanded Access in Pancreatic Cancer

N/A

Clinical Trials (1)

NCT05683470Expanded Access RBS2418 Treatment

N/A

Help build intelligence for Riboscience

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead development of novel ribose-based therapeutic modality with potential for differentiated mechanism in oncology
Early-stage growth opportunity with RBS2418 in Phase 2 for multiple high-mortality cancers (HCC, colorectal, pancreatic)
Clinical Operations team actively hiring (3 open roles) suggests acceleration of trial expansion

Watch Out For

Pre-revenue status with unknown funding creates uncertainty around runway and job security
No Phase 3 programs or marketed products limits near-term commercialization catalysts and revenue visibility
Minimal employee and financial data suggests early-stage or opaque operations

Generated by Claude from Riboscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RBS2418

Advanced Cancer

Phase 1

Clinical Trials (1)

NCT05270213Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Phase 1

RBS2418

Advanced Unresectable Hepatocellular Carcinoma

Phase 2

Clinical Trials (1)

NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Phase 2

RBS2418

Metastatic Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT06824064Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline